健康（Health）
美容（Beauty）
ウェルネス（Wellness）
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Scrip: 世界の医療用医薬品＆製薬産業に関するニ...
Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.
Biomedtracker: 開発中医薬品をFDA承認確率で評価
This is both an updated study of clinical drug development success rates from our 2016 report, and an expansion into the drivers of success with the addition of machine learning modeling to analyze the predictive factors contributing to drug development.
Topic Clinical Trials Drug Development Landscape Drug Pricing
Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...
COVID-19による治験動向の変化を検証するホワイトペーパーです。製薬企業はCOVID-19のワクチン・治療薬の開発を優先し、その他領域の治験には中断や遅れが生じています。一方、遠隔医療・バーチャル治験・電子的データ管理等が急速に普及しつつあります。
Topic Coronavirus Clinical Trials
Biomedtracker: 開発中医薬品をFDA承認確率で評価
欧州最大規模のバイオテック・パートナリングイベントBIO-Europe Fallが、BIO-Europe DIGITAL 2020として開催。2020年上半期に完了したバイオ医薬品業界の提携及び資金調達取引など、バイオ医薬品業界の新たな動向を明らかにします。
Topic Bio-Europe
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...
Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.
Topic Coronavirus
Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...
The effect of COVID-19 on clinical trials, the industry response, and the return to full operations
Topic Coronavirus clinical-trials
Biomedtracker: 開発中医薬品をFDA承認確率で評価
In preparation for the webinar, download your free infographic, a snapshot view of M&A’s biggest deals and major players and what their activities indicate for the year ahead.
Topic M A
Biomedtracker: 開発中医薬品をFDA承認確率で評価
Using M&A activity as a barometer for the overall health of the biopharma industry, we explore biopharma’s biggest deals of the past decade and examine what they may presage for the year to come. Dive into key insights on trends, M&A drivers, companies to watch, and more.
Topic M A
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetracker: 医療機器の市場調...
The world-class data contained in this report extract will keep you up to speed on the drug development landscape for better decision-making
Biomedtracker: 開発中医薬品をFDA承認確率で評価
Get an inside view into the trends powering COVID-era deal making in the life sciences with your free copy of “Biopharma Partnering and Financing Trends, H1 2020”. Informa Pharma Intelligence takes you inside the forces shaping the industry
Topic Bio-Europe
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...
Valuable insight and expert analyst commentary 2021’s expected drug launches, their indications, commercial potential, regulatory catalysts and more.
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Pharma consulting: 医療用医薬品の...
Catch up on any missed COVID-19 24 hour webinar sessions
Topic Cardiovascular Coronavirus
Pharmaprojects: 医薬品開発パイプラインのデータベース, Biomedtracker: 開発中医薬品をFD...
Access this infographic which focuses on Gilead’s drug Remdesivir which currently shows the greatest promise for the likelihood of approval as a possible treatment to effectively treat the virus. The infographic highlights the drug summary and profile, the number of patients in each trial phase, and the history of events that have moved this product through the development process.
Topic Coronavirus FDA Drug Review
Biomedtracker: 開発中医薬品をFDA承認確率で評価
In this infographic, we provide insight into key trials that are expecting developments in the approval process.
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...
Anticipate the biggest, most impactful expected catalysts of early 2020 with the guidance and insights from Pharma Intelligence. Building off Biomedtracker’s Early 2020 Outlook report, our live webinar will include market context for these upcoming milestones and additional insights from Datamonitor Healthcare’s Therapeutic Area Directors.
Topic fda
UK
Richard specializes in
+27 year(s) experience
Washington DC, USA
Eileen specializes in
+20 year(s) experience
USA
Ryan specializes in
+16 year(s) experience
無料トライアルお申込み
お問い合わせ先
新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問合せの際は下記メールアドレスまたは各営業スタッフまでご連絡下さいますようご協力をお願い申し上げます。
インフォーマインテリジェンス合同会社
ファーマインテリジェンス
inquiry.jp@informa.com
＊Omdia（ICT産業の情報）に関するお問い合わせはこちら
Contact_OmdiaJapan@omdia.com
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
